A5040803542- Dermatology and Skin Diseases
- Hair Growth and Disorders
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Urticaria and Related Conditions
- Autoimmune Bullous Skin Diseases
- Acne and Rosacea Treatments and Effects
- RNA regulation and disease
- IL-33, ST2, and ILC Pathways
- Contact Dermatitis and Allergies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- melanin and skin pigmentation
- Cutaneous Melanoma Detection and Management
- Skin Protection and Aging
- Cutaneous lymphoproliferative disorders research
- Immune Cell Function and Interaction
- Dermatologic Treatments and Research
- Social Media in Health Education
- Food Allergy and Anaphylaxis Research
- Nail Diseases and Treatments
- Psoriasis: Treatment and Pathogenesis
- Colorectal and Anal Carcinomas
- Artificial Intelligence in Healthcare and Education
- Pharmacological Effects of Natural Compounds
Icahn School of Medicine at Mount Sinai
2016-2025
Mount Sinai Health System
2024
Mount Sinai Medical Center
2015-2024
Nationwide Children's Hospital
2023
Sheba Medical Center
2022
Centre National de la Recherche Scientifique
2022
Aix-Marseille Université
2022
Inserm
2022
Rockefeller University
2015-2018
The Spine Institute
2011
Dupilumab is an IL-4 receptor α mAb inhibiting signaling of and IL-13, key drivers type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases.This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, effects dupilumab on molecular/cellular lesional nonlesional skin phenotypes systemic 2 biomarkers moderate-to-severe atopic dermatitis (AD).Skin biopsy specimens blood were from 54 randomized 1:1 to weekly subcutaneous...
A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis. Patients were randomly assigned receive placebo, 30 mg twice daily (APR30), or 40 (APR40) for 12 weeks. During weeks 12–24, all patients received APR30 APR40. biopsy substudy dermatitis-related biomarkers. Among 185 intent-to-treat at week 12, a dose-response relationship was observed; APR40 (n = 63), but not 58), led statistically...
Purpose This study aims to explore the effectiveness of low-dose oral minoxidil (LDOM) in treating short anagen hair syndrome (SAS), a rare congenital condition characterized by shortened phase. While SAS often resolves spontaneously with puberty, treatment remains controversial. Recent studies have demonstrated efficacy various loss conditions, including SAS.
Atopic dermatitis (AD) presents a large unmet need for treatments with better safety and efficacy. To facilitate development of topical therapeutics, we an efficient model assessing different formulations concentrations. The "plaque model" has been successfully implemented in patients psoriasis, another common inflammatory disease, to assess the efficacy treatments. This not validated AD, which higher placebo responses less stable lesions than psoriasis.We aimed changes molecular signatures...
In the SARS-CoV-2/COVID-19 pandemic, we need to understand impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including type 2/Th2 polarized skin disease, atopic dermatitis (AD).Because it is believed that 1/Th1 immunity controls viral infections and there a Th1/Th2 counter-regulation, hypothesized Th2 targeting IL-4Rα-antagonist, dupilumab, moderate-to-severe AD would rebalance axis, potentially leading attenuated symptoms.A total...
Abstract Background In atopic dermatitis (AD), some studies have shown an association with increased cardiovascular disease in certain populations. However, other investigations found modest or no association. Despite conflicting results, molecular profiling both AD skin and blood demonstrated upregulation of atherosclerosis risk‐related markers. the underlying mechanisms connecting to vascular inflammation/atherosclerosis are unknown. this study, we aim determine factors associated...
Tape-strips are a minimally invasive approach to characterize skin biomarkers in atopic dermatitis (AD). However, they have not yet been used for tracking gene expression changes with systemic treatment.The aim of the study was evaluate and therapeutic response AD patients before after dupilumab (interleukin 4Rα antibody) treatment using tape-strips obtain epidermal tissue analysis.Lesional nonlesional tape-stripped sampled from 18 17 healthy subjects analyzed by RNA-seq.At baseline, we...